Roche

Diversified pharma

RHHBY · OTC · Switzerland

Share price · RHHBY

$55.53+4.43 (+8.67%) 3M

no price since 18 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RHHBY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 23 Jul 2026+4.3%
  2. 13 Jul 2026-2.7%
  3. 2 Jul 2026+5.4%
  4. 1 Jul 2026-2.0%
  5. 1 Jun 2026-4.2%
  6. 13 Mar 2026-3.5%
  7. 5 Mar 2026-6.3%
  8. 29 Jan 2026+4.8%
  9. 18 Nov 2025+9.6%
  10. 10 Nov 2025+4.5%

Share of unusual movement by asset

For each asset, the share of RHHBY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Bitopertin
events and moves
83%
Obinutuzumab
events and moves
4shown from 8 days
bexobrutideg
events and moves
4shown from 8 days
Baxdrostat (Baxfendy)
events and moves
4shown from 8 days
Atezolizumab
events and moves
3shown from 8 days
petrelintide
events and moves
2shown from 8 days
Divarasib
events and moves
2shown from 8 days
Inavolisib (Itovebi)
events and moves
2shown from 8 days
Zilebesiran
events and moves
1shown from 8 days
astegolimab
events and moves
1shown from 8 days
Prasinezumab
events and moves
1shown from 8 days
Ocrelizumab
events and moves
1shown from 8 days
Ocrevus Zunovo (Ocrevus Zunovo)
events and moves
1shown from 8 days
Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
events and moves
1shown from 8 days
Venetoclax
events and moves
1shown from 8 days
Giredestrant
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—12%
Other company news (earnings, financing, releases naming no asset)—5%
Sessions with no dated event—80%

Assets

(68 total)
68Total Assets
23Approved
17Phase 3 / Filed
28Phase 1–2 / Early
58Diseases
Quick filter:
Showing 68 of 68 assets
Target & Modality
Alectinib(Alecensa)
Approved
ALKSmall molecule
Non-Small Cell Lung Cancer
Approved
PD-L1Monoclonal antibody
Non-Small Cell Lung CancerHepatocellular CarcinomaColorectal CancerBladder CancerSmall Cell Lung CancerMelanoma
Baxdrostat(Baxfendy)
Approved
Aldosterone synthase (CYP11B2)Small molecule
HypertensionHeart FailureChronic Kidney Disease
Approved
VEGF-A · Vascular Endothelial Growth Factor InhibitorMonoclonal antibody
Non-Small Cell Lung CancerOvarian CancerCervical CancerHepatocellular CarcinomaColorectal CancerRenal Cell CarcinomaGlioblastoma
Metastatic Colorectal Cancer, Recurrent Glioblastoma
Approved
MEK1/2Small molecule
Melanoma
Approved
ROS1/NTRKSmall molecule
Non-Small Cell Lung Cancer
Approved
Angiopoietin-2 / VEGF-AMultispecific antibody
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Inavolisib(Itovebi)
Approved
PI3K-alphaSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
CD20Monoclonal antibody
Follicular LymphomaPrimary Membranous NephropathyLupus NephritisNon-Hodgkin LymphomaChronic Lymphocytic Leukemia
Approved
CD20Monoclonal antibody
Multiple Sclerosis
Approved
CD20Monoclonal antibody
Multiple Sclerosis
Omalizumab(Xolair)
Approved
IgE (immunoglobulin E) · IgEMonoclonal antibody
AsthmaChronic Spontaneous Urticaria
Approved
Type I interferon receptor
Chronic Hepatitis B
Approved
HER2/neu Receptor AntagonistMonoclonal antibody
Breast Cancer
HER2-Positive Breast Cancer
Approved
PyridoneSmall molecule
Idiopathic Pulmonary Fibrosis

Discontinued programmes (3)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(129 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (3)
VenetoclaxPhase 2Chronic Lymphocytic Leukemia (CLL)
Est. primary completion 2026-11 · NCT04895436 · CT.gov ↗
What to watch
Est. primary completion 2026-11-30 · NCT04302025 · CT.gov ↗
What to watch
AtezolizumabPhase 3Cancer
Est. primary completion 2026-11-30 · NCT03148418 · CT.gov ↗
What to watch
December 2026 (4)
Est. primary completion 2026-12-01 · NCT03758989 · CT.gov ↗
What to watch
Baxdrostat · BaxfendyPhase 2Chronic Kidney Disease and Hypertension
Est. primary completion 2026-12-10 · NCT07222917 · CT.gov ↗
What to watch
Obinutuzumab + tocilizumab · Actemra / RoActemraPhase 1/2Lymphoma, Non-Hodgkin
Est. primary completion 2026-12-28 · NCT04077723 · CT.gov ↗
What to watch
afimkibartPhase 2Crohns Disease
Est. primary completion 2026-12-31 · NCT05910528 · CT.gov ↗
What to watch
2027 (38)
January 2027 (4)
Tambotatug pelitecanPhase 1/2Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
Est. primary completion 2027-01 · NCT07208773 · CT.gov ↗
What to watch
Alectinib · Alecensa + EntrectinibPhase 3Non-Small Cell Lung Cancer
Est. primary completion 2027-01-19 · NCT05170204 · CT.gov ↗
What to watch
2026-12-31 Financial ReportEarnings report
Expected report date 2027-01-28 · Fiscal period ending 2026-12-31
What to watch
afimkibartPhase 3Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2027-01-30 · NCT06589986 · CT.gov ↗
What to watch
February 2027 (3)
VenetoclaxPhase 1/2Acute Myeloid Leukemia
Est. primary completion 2027-02 · NCT04086264 · CT.gov ↗
What to watch
Tambotatug pelitecanPhase 2Metastatic Castration-resistant Prostate Cancer (mCRPC)
Est. primary completion 2027-02 · NCT06241846 · CT.gov ↗
What to watch
Est. primary completion 2027-02-26 · NCT05535244 · CT.gov ↗
What to watch
March 2027 (2)
PertuzumabPhase 3Solid Tumors
Est. primary completion 2027-03-28 · NCT02320435 · CT.gov ↗
What to watch
AtezolizumabPhase 3Breast Cancer
Est. primary completion 2027-03-31 · NCT04873362 · CT.gov ↗
What to watch
April 2027 (2)
Tambotatug pelitecanPhase 1/2Advanced Solid Tumor
Est. primary completion 2027-04-06 · NCT05434234 · CT.gov ↗
What to watch
afimkibartPhase 2Rheumatoid Arthritis
Est. primary completion 2027-04-17 · NCT07137598 · CT.gov ↗
What to watch
May 2027 (1)
Inavolisib · ItovebiPhase 3Metastatic Breast Cancer
Est. primary completion 2027-05-03 · NCT05894239 · CT.gov ↗
What to watch
June 2027 (7)
VenetoclaxPhase 2Multiple Myeloma
Est. primary completion 2027-06 · NCT02899052 · CT.gov ↗
What to watch
FenebrutinibPhase 2Relapsing Multiple Sclerosis
Est. primary completion 2027-06-08 · NCT07161258 · CT.gov ↗
What to watch
EntrectinibPhase 1/2Solid Tumors, CNS Tumors
Est. primary completion 2027-06-30 · NCT02650401 · CT.gov ↗
What to watch
Atezolizumab + Pertuzumab + Trastuzumab EmtansinePhase 2Neoplasm Metastasis
Est. primary completion 2027-06-30 · NCT00781612 · CT.gov ↗
What to watch
Est. primary completion 2027-06-30 · NCT03178552 · CT.gov ↗
What to watch
astegolimabPhase 3Chronic Obstructive Pulmonary Disease
Est. primary completion 2027-06-30 · NCT05878769 · CT.gov ↗
What to watch
Atezolizumab + BevacizumabPhase 3Neoplasms
Est. primary completion 2027-06-30 · NCT05112965 · CT.gov ↗
What to watch
July 2027 (7)
VenetoclaxPhase 3Myelodysplastic Syndrome (MDS)
Est. primary completion 2027-07 · NCT04401748 · CT.gov ↗
What to watch
Baxdrostat · BaxfendyPhase 3Primary Hyperaldosteronism
Est. primary completion 2027-07-27 · NCT07007793 · CT.gov ↗
What to watch
Est. primary completion 2027-07-30 · NCT04524871 · CT.gov ↗
What to watch
Atezolizumab + BevacizumabPhase 2Hepatocellular Carcinoma
Est. primary completion 2027-07-30 · NCT06096779 · CT.gov ↗
What to watch
TrontinemabPhase 1/2Alzheimers Disease
Est. primary completion 2027-07-31 · NCT04639050 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 2DLBCL, Lymphoma, B-Cell
Est. primary completion 2027-07-31 · NCT04594798 · CT.gov ↗
What to watch
Inavolisib · ItovebiPhase 2Breast Cancer
Est. primary completion 2027-07-31 · NCT07054190 · CT.gov ↗
What to watch
August 2027 (4)
VenetoclaxPhase 3Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
Est. primary completion 2027-08 · NCT03844048 · CT.gov ↗
What to watch
vixarelimabPhase 2Ulcerative Colitis
Est. primary completion 2027-08-25 · NCT06979336 · CT.gov ↗
What to watch
Pertuzumab + Trastuzumab Emtansine + BizrolertinibPhase 1/2Advanced Solid Tumors, HER2-positive Breast Cancer
Est. primary completion 2027-08-31 · NCT05593094 · CT.gov ↗
What to watch
Est. primary completion 2027-08-31 · NCT06084936 · CT.gov ↗
What to watch
September 2027 (1)
ZemocimigPhase 3Hemophilia A
Est. primary completion 2027-09-23 · NCT07416526 · CT.gov ↗
What to watch
October 2027 (2)
tocilizumab · Actemra / RoActemraPhase 2Non-Hodgkin Lymphoma
Est. primary completion 2027-10-01 · NCT05207670 · CT.gov ↗
What to watch
Rituximab · RituxanPhase 3Large B-Cell Lymphoma
Est. primary completion 2027-10-01 · NCT06047080 · CT.gov ↗
What to watch
November 2027 (2)
Autogene cevumeranPhase 2Muscle-invasive Urothelial Carcinoma
Est. primary completion 2027-11-10 · NCT06534983 · CT.gov ↗
What to watch
enicepatide + petrelintidePhase 2Obesity or Overweight
Est. primary completion 2027-11-12 · NCT07589686 · CT.gov ↗
What to watch
December 2027 (3)
Tambotatug pelitecanPhase 3Small Cell Lung Cancer
Est. primary completion 2027-12-01 · NCT06612151 · CT.gov ↗
What to watch
Tambotatug pelitecanPhase 3Nasopharyngeal Carcinoma
Est. primary completion 2027-12-01 · NCT06629597 · CT.gov ↗
What to watch
OcrelizumabPhase 3Multiple Sclerosis
Est. primary completion 2027-12-31 · NCT05269004 · CT.gov ↗
What to watch
2028 (40)
January 2028 (2)
bexobrutidegPhase 2Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Est. primary completion 2028-01 · NCT07221500 · CT.gov ↗
What to watch
SelnoflastPhase 2Atherosclerosis
Est. primary completion 2028-01-31 · NCT07448038 · CT.gov ↗
What to watch
February 2028 (9)
Tambotatug pelitecanPhase 1/2Recurrent or Metastatic Nasopharyngeal Carcinoma
Est. primary completion 2028-02 · NCT07258979 · CT.gov ↗
What to watch
TifeglipronPhase 2Type 2 Diabetes Mellitus
Est. primary completion 2028-02-05 · NCT07112872 · CT.gov ↗
What to watch
Baxdrostat · BaxfendyPhase 3Uncontrolled Hypertension
Est. primary completion 2028-02-09 · NCT07686120 · CT.gov ↗
What to watch
TrontinemabPhase 3Alzheimers Disease
Est. primary completion 2028-02-16 · NCT07169578 · CT.gov ↗
What to watch
TrontinemabPhase 3Alzheimers Disease
Est. primary completion 2028-02-16 · NCT07170150 · CT.gov ↗
What to watch
Baxdrostat · BaxfendyPhase 3Chronic Kidney Disease and Hypertension
Est. primary completion 2028-02-24 · NCT06268873 · CT.gov ↗
What to watch
enicepatidePhase 3Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
Est. primary completion 2028-02-24 · NCT07670416 · CT.gov ↗
What to watch
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
ZemocimigPhase 3Hemophilia A
Est. primary completion 2028-02-29 · NCT07416604 · CT.gov ↗
What to watch
March 2028 (3)
VenetoclaxPhase 3Chronic Lymphocytic Leukemia
Est. primary completion 2028-03 · NCT06428019 · CT.gov ↗
What to watch
Inavolisib · ItovebiPhase 2Metastatic Castration-Resistant Prostate Cancer
Est. primary completion 2028-03-31 · NCT07287150 · CT.gov ↗
What to watch
Obinutuzumab + tocilizumab · Actemra / RoActemraPhase 3Diffuse Large B-cell Lymphoma
Est. primary completion 2028-03-31 · NCT04408638 · CT.gov ↗
What to watch
April 2028 (2)
GiredestrantPhase 3Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Est. primary completion 2028-04-20 · NCT06065748 · CT.gov ↗
What to watch
Tambotatug pelitecanPhase 3Advanced Esophageal Squamous Cell Carcinoma
Est. primary completion 2028-04-30 · NCT07487896 · CT.gov ↗
What to watch
May 2028 (3)
Omalizumab · XolairPhase 3Chronic Spontaneous Urticaria
Est. primary completion 2028-05-24 · NCT07816328 · CT.gov ↗
What to watch
SefaxersenPhase 3Primary IgA Nephropathy
Est. primary completion 2028-05-25 · NCT05797610 · CT.gov ↗
What to watch
afimkibartPhase 3Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2028-05-31 · NCT07846683 · CT.gov ↗
What to watch
June 2028 (4)
BitopertinPhase 2/3Erythropoietic Protoporphyria
Est. primary completion 2028-06 · NCT05883748 · CT.gov ↗
What to watch
ObinutuzumabPhase 2Lupus Nephritis
Est. primary completion 2028-06-15 · NCT05039619 · CT.gov ↗
What to watch
Pertuzumab + GiredestrantPhase 3Locally Advanced or Metastatic Breast Cancer
Est. primary completion 2028-06-15 · NCT05296798 · CT.gov ↗
What to watch
PegozaferminPhase 3Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Est. primary completion 2028-06-30 · NCT06419374 · CT.gov ↗
What to watch
July 2028 (4)
VenetoclaxPhase 2Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
Est. primary completion 2028-07 · NCT07387471 · CT.gov ↗
What to watch
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
enicepatidePhase 3Obesity or Overweight
Est. primary completion 2028-07-24 · NCT07351045 · CT.gov ↗
What to watch
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch
August 2028 (2)
enicepatidePhase 3Obesity or Overweight, Type 2 Diabetes Mellitus
Est. primary completion 2028-08-07 · NCT07351058 · CT.gov ↗
What to watch
Vustanaciclib + GiredestrantPhase 1/2Breast Cancer
Est. primary completion 2028-08-31 · NCT07100106 · CT.gov ↗
What to watch
September 2028 (1)
ZemocimigPhase 3Hemophilia A
Est. primary completion 2028-09-30 · NCT07838194 · CT.gov ↗
What to watch
October 2028 (2)
petrelintidePhase 3Obesity or Overweight, Type 2 Diabetes
Est. primary completion 2028-10-20 · NCT07843485 · CT.gov ↗
What to watch
Inavolisib · ItovebiPhase 2Breast Cancer
Est. primary completion 2028-10-31 · NCT07368998 · CT.gov ↗
What to watch
November 2028 (4)
Tambotatug pelitecanPhase 1/2Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
Est. primary completion 2028-11 · NCT07407933 · CT.gov ↗
What to watch
DivarasibPhase 3Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Est. primary completion 2028-11-30 · NCT06793215 · CT.gov ↗
What to watch
CevostamabPhase 3Multiple Myeloma
Est. primary completion 2028-11-30 · NCT07555938 · CT.gov ↗
What to watch
GiredestrantPhase 3Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
Est. primary completion 2028-11-30 · NCT07827573 · CT.gov ↗
What to watch
December 2028 (4)
Inavolisib · ItovebiPhase 2Breast Cancer
Est. primary completion 2028-12-19 · NCT07405801 · CT.gov ↗
What to watch
petrelintidePhase 3Obesity or Overweight
Est. primary completion 2028-12-21 · NCT07843498 · CT.gov ↗
What to watch
afimkibartPhase 3Moderately to Severely Active Crohns Disease
Est. primary completion 2028-12-31 · NCT06819878 · CT.gov ↗
What to watch
afimkibartPhase 3Moderately to Severely Active Crohns Disease
Est. primary completion 2028-12-31 · NCT06819891 · CT.gov ↗
What to watch
2029 (20)
January 2029 (1)
Tambotatug pelitecanPhase 3Metastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Est. primary completion 2029-01 · NCT07803783 · CT.gov ↗
What to watch
February 2029 (3)
PegozaferminPhase 3Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Est. primary completion 2029-02 · NCT06318169 · CT.gov ↗
What to watch
VenetoclaxPhase 2Acute Myeloid Leukemia (AML)
Est. primary completion 2029-02-01 · NCT07423104 · CT.gov ↗
What to watch
Atezolizumab + BevacizumabPhase 3Hepatocellular Carcinoma
Est. primary completion 2029-02-01 · NCT04712643 · CT.gov ↗
What to watch
March 2029 (1)
Obinutuzumab + tocilizumab · Actemra / RoActemraPhase 1/2Non-Hodgkin's Lymphoma
Est. primary completion 2029-03-30 · NCT03075696 · CT.gov ↗
What to watch
April 2029 (2)
enicepatidePhase 3Type 2 Diabetes Mellitus
Est. primary completion 2029-04-02 · NCT07889648 · CT.gov ↗
What to watch
Est. primary completion 2029-04-13 · NCT07825064 · CT.gov ↗
What to watch
May 2029 (2)
BizrolertinibPhase 2/3HER2-positive Breast Cancer
Est. primary completion 2029-05-01 · NCT07413939 · CT.gov ↗
What to watch
Atezolizumab + Inavolisib · ItovebiPhase 1/2Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
June 2029 (3)
Tambotatug pelitecanPhase 3SCLC, Extensive Stage
Est. primary completion 2029-06 · NCT07739758 · CT.gov ↗
What to watch
Inavolisib · ItovebiPhase 2Breast Cancer, Diabetes Type II
Est. primary completion 2029-06-15 · NCT07748208 · CT.gov ↗
What to watch
PrasinezumabPhase 3Parkinson's Disease
Est. primary completion 2029-06-30 · NCT07174310 · CT.gov ↗
What to watch
July 2029 (1)
ObinutuzumabPhase 2Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Est. primary completion 2029-07-31 · NCT06806033 · CT.gov ↗
What to watch
August 2029 (1)
OcrelizumabPhase 2Relapsing-remitting Multiple Sclerosis
Est. primary completion 2029-08-31 · NCT07503340 · CT.gov ↗
What to watch
October 2029 (1)
bexobrutidegPhase 3B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Est. primary completion 2029-10 · NCT07516093 · CT.gov ↗
What to watch
November 2029 (2)
Obinutuzumab + Rituximab · Rituxan + tocilizumab · Actemra / RoActemraPhase 1/2Mature B-Cell Non-Hodgkin Lymphoma
Est. primary completion 2029-11-30 · NCT05533775 · CT.gov ↗
What to watch
FenebrutinibPhase 3Multiple Sclerosis
Est. primary completion 2029-11-30 · NCT07937852 · CT.gov ↗
What to watch
December 2029 (3)
Baxdrostat · BaxfendyPhase 3Heart Failure
Est. primary completion 2029-12-17 · NCT06677060 · CT.gov ↗
What to watch
Baxdrostat · BaxfendyPhase 3Chronic Kidney Disease and Hypertension
Est. primary completion 2029-12-18 · NCT06742723 · CT.gov ↗
What to watch
OcrelizumabPhase 3Multiple Sclerosis
Est. primary completion 2029-12-31 · NCT06675955 · CT.gov ↗
What to watch
2030 (7)
March 2030 (1)
afimkibartPhase 3Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2030-03-31 · NCT07158242 · CT.gov ↗
What to watch
May 2030 (1)
afimkibartPhase 3Moderately to Severely Active Crohns Disease
Est. primary completion 2030-05-31 · NCT07298421 · CT.gov ↗
What to watch
July 2030 (1)
petrelintidePhase 3Obesity or Overweight, Cardiovascular Disease
Est. primary completion 2030-07-28 · NCT07843472 · CT.gov ↗
What to watch
September 2030 (3)
tocilizumab · Actemra / RoActemraPhase 1/2Follicular Lymphoma
Est. primary completion 2030-09-06 · NCT04246086 · CT.gov ↗
What to watch
ZilebesiranPhase 3High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Est. primary completion 2030-09-23 · NCT07181109 · CT.gov ↗
What to watch
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
December 2030 (1)
VenetoclaxPhase 2Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Est. primary completion 2030-12 · NCT02966756 · CT.gov ↗
What to watch
2031 (4)
January 2031 (1)
Atezolizumab + Autogene cevumeranPhase 2Adenocarcinoma, Pancreatic Ductal
Est. primary completion 2031-01-01 · NCT05968326 · CT.gov ↗
What to watch
March 2031 (2)
OpRegenPhase 2Geographic Atrophy
Est. primary completion 2031-03-01 · NCT05626114 · CT.gov ↗
What to watch
enicepatidePhase 3Overweight, Obesity, Cardiovascular Disease
Est. primary completion 2031-03-20 · NCT07918846 · CT.gov ↗
What to watch
May 2031 (1)
VenetoclaxPhase 2Multiple Myeloma
Est. primary completion 2031-05 · NCT03314181 · CT.gov ↗
What to watch
2032 (8)
January 2032 (3)
DivarasibPhase 1/2Non-Small Cell Lung Cancer
Est. primary completion 2032-01-29 · NCT05789082 · CT.gov ↗
What to watch
DivarasibPhase 3Non-small Cell Lung Cancer
Est. primary completion 2032-01-31 · NCT07541170 · CT.gov ↗
What to watch
Inavolisib · ItovebiPhase 3Breast Cancer
Est. primary completion 2032-01-31 · NCT06790693 · CT.gov ↗
What to watch
February 2032 (1)
Alectinib · AlecensaPhase 1/2ALK Fusion-positive Solid or CNS Tumors
Est. primary completion 2032-02-28 · NCT04774718 · CT.gov ↗
What to watch
June 2032 (2)
VenetoclaxPhase 2/3Acute Myeloid Leukemia
Est. primary completion 2032-06 · NCT07581002 · CT.gov ↗
What to watch
GiredestrantPhase 3Early Breast Cancer
Est. primary completion 2032-06-30 · NCT07541079 · CT.gov ↗
What to watch
July 2032 (1)
TrontinemabPhase 3Alzheimer's Disease
Est. primary completion 2032-07-30 · NCT07717411 · CT.gov ↗
What to watch
September 2032 (1)
Est. primary completion 2032-09-25 · NCT04589845 · CT.gov ↗
What to watch
2033 (5)
March 2033 (2)
afimkibartPhase 2Atopic Dermatitis
Est. primary completion 2033-03-01 · NCT07223697 · CT.gov ↗
What to watch
Est. primary completion 2033-03-01 · NCT05862285 · CT.gov ↗
What to watch
May 2033 (1)
bexobrutidegPhase 1/2B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Est. primary completion 2033-05 · NCT07520006 · CT.gov ↗
What to watch
July 2033 (1)
afimkibartPhase 2Rheumatoid Arthritis
Est. primary completion 2033-07-08 · NCT07620392 · CT.gov ↗
What to watch
December 2033 (1)
ZemocimigPhase 1/2Hemophilia A
Est. primary completion 2033-12-11 · NCT05987449 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(29)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026FDA action dateObinutuzumabFDA decision on Gazyva in primary membranous nephropathy expected by November 2026
US, FDA · Source ↗
November 2026ApprovalObinutuzumabFDA approves Gazyva in primary membranous nephropathy
US, FDA · Source ↗
30 November 2026FDA action dateGiredestrantFDA goal date for adjuvant giredestrant NDA
US, FDA · Roche · Source ↗
18 December 2026FDA action dateGiredestrantGiredestrant plus everolimus NDA PDUFA date
US, FDA · Roche (Genentech) · Source ↗
July 2027FDA action dateVamikibartFDA decision expected by July 2027
US, FDA · Source ↗

Recent

16 November 2026ApprovalGiredestrantFDA approves Wilserdly (giredestrant) plus everolimus in ESR1-mutated advanced breast cancer
US, FDA · Source ↗
19 October 2026Topline resultBitopertinPhase 3 APOLLO of bitopertin in EPP met both co-primary endpoints
Disc Medicine · Source ↗
15 October 2026ApprovalOcrelizumabEuropean Commission approves Ocrevus for paediatric RRMS
EU, EC · Source ↗
10 October 2026Filing acceptedVamikibartFDA accepts vamikibart BLA for UME
US, FDA · Source ↗
9 October 2026ApprovalAtezolizumabFDA approves Tecentriq for adjuvant stage III dMMR colon cancer
US, FDA · Roche · Source ↗
7 October 2026Topline resultpetrelintideZUPREME-2 Phase 2 trial met its primary endpoint
Zealand Pharma A/S · Source ↗
23 September 2026Topline resultIONIS-FB-LRx (sefaxersen)Phase 3 IMAgINATION (NCT05797610) met its proteinuria primary endpoint at a prespecified interim analysis
Roche · Source ↗
22 September 2026Topline resultenicepatideCT-388-104 Phase 2 (NCT06628362) in type 2 diabetes met both primary endpoints (HbA1c and body weight)
Roche · Source ↗
13 September 2026Topline resultYL201Phase 3 TAISHAN-302 (NCT06612151) met its overall survival primary endpoint at interim analysis
MediLink Therapeutics (reported by its collaborator Roche) · Source ↗
28 August 2026Topline resultAutogene cevumeranPhase 2 BNT122-01 (NCT04486378) terminated for futility with overall survival numerical imbalance
BioNTech · Source ↗
15 July 2026Priority reviewObinutuzumabFDA grants Priority Review to Gazyva sBLA in primary membranous nephropathy
US, FDA · Source ↗
2 July 2026Topline resultDivarasibKrascendo 1 Phase 3 meets primary and key secondary endpoint
Roche · Source ↗

The 12 most recent of 24 past events are shown.

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$37.2B———report ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$35.9B$7.7B$15.2B—report ↗
2024-H1$33.6B$8.3B$9.8B—report ↗
2023-H1$32.7B$7.6B$8.4B—report ↗
2022-H1$34.2B$7.3B$7.1B—report ↗
2021-H1$33.8B$7.8B$8.7B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$74.2B$14.7B——report ↗

Roche reported revenue of $74,172.62M, up 8.0% YoY, and R&D spend of $14,710.09M, down 0.4% YoY. Cash position was not disclosed; core operating profit was CHF 21,833M, up 13% YoY at CER, and IFRS net income was CHF 13,799M, up 58% YoY at CER.

For 2026, Roche guided to mid single-digit Group sales growth and high single-digit core EPS growth at CER, with a further dividend increase planned. Pipeline highlights included US and EU approvals for subcutaneous Lunsumio, EU approval of Gazyva/Gazyvaro for lupus nephritis, positive phase III results for giredestrant, fenebrutinib, and other programs, and positive phase II data for CT-388; 10 key molecules advanced into phase III. Roche also completed its 89bio tender offer, obtained CE marks for diagnostic tests, and proposed a CHF 9.80 per share dividend, which would be the 39th consecutive increase.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$68.7B$14.8B——report ↗
2023-FY$65.4B$14.3B——report ↗
2022-FY$66.3B$16.8B$10.6B—report ↗
2021-FY$68.7B$16.2B$14.3B—report ↗

Insider transactions

Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 67 reporting institutions held 5.6M shares ($251.8M, 0.1% of shares outstanding).

#InstitutionSharesValue
1Aristotle Capital Management, LLC2,063,885$102.1M
2Saratoga Research & Investment Management1,291,630$64.2M
3Boston Common Asset Management, LLC322,354$16.0M
4OLD NATIONAL BANCORP /IN/257,854$12.6M
5Altrius Capital Management Inc176,959$8.8M
6HUNTINGTON NATIONAL BANK122,990$6.0M
7RHUMBLINE ADVISERS98,944$4.9M
8OPAL CAPITAL LLC89,483$4.4M
9Sterling Capital Management LLC62,962$3.1M
10KORNITZER CAPITAL MANAGEMENT INC /KS61,873$3.0M
11Diversified Trust Co59,375$2.9M
12YOUSIF CAPITAL MANAGEMENT, LLC52,832$2.6M
13Patrick Mauro Investment Advisor, INC.45,578$2.3M
14Wallington Asset Management, LLC40,264$2.0M
15Associated Banc-Corp33,295$1.6M